feed,title,long_url,short_url
Benzinga,"Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs",https://benzinga.com/general/biotech/22/03/26241837/orphazyme-withdraws-european-application-for-arimoclomol-initiates-delisting-of-its-adss,https://bit.ly/3wstXiZ
Benzinga,Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder,https://benzinga.com/general/biotech/22/03/26240782/argenxs-subcutaneous-efgartigimod-at-par-with-intravenous-administration-in-neuromuscular-disorde,https://bit.ly/3Iulez9
Benzinga,NightDragon Forms Strategic Alliance With Jacobs Engineering,https://benzinga.com/news/22/03/26243133/nightdragon-forms-strategic-alliance-with-jacobs-engineering,https://bit.ly/3ipVo55
Benzinga,FDA Gives Green Signal For Palisade Bio's LB1148 Phase 3 Study,https://benzinga.com/general/biotech/22/03/26239955/fda-gives-green-signal-for-palisade-bios-lb1148-phase-3-study,https://bit.ly/3Jszud8
